Paradigm Health Acquires Flatiron Clinical Research Arm, Raises $78M to Broaden Trial Access
The acquisition and Series B funding round enable Paradigm to significantly expand its oncology network, serve 15 of the top 20 global biopharma companies, and integrate AI into trial management.
Paradigm Health has completed the acquisition of Flatiron Health’s clinical research business shortly after successfully raising $78 million in a Series B financing round.
Network Expansion and Reach
-
Network Growth: With the acquisition, Paradigm’s network has expanded to encompass more than 25 medical centers and nearly 100 community oncology practices across the United States.
-
Customer Base: The enlarged network now enables Paradigm to serve 15 of the top 20 global biopharma companies.
-
Trial Capacity: Paradigm CEO Kent Thoelke framed the deal as a major step toward “accelerating our impact in the US so that more trials can happen where patients actually receive care,” and adds capacity to run pragmatically designed Phase IV trials.
Technology Collaboration and AI Integration
Although the financial terms of the acquisition were not disclosed, the two companies have agreed to a long-term technology collaboration.
-
AI Integration: The plan involves integrating Paradigm’s AI technology into Flatiron’s clinical trial management software.
-
Vision: Flatiron CEO Nathan Hubbard noted that combining Paradigm’s AI-powered infrastructure with Flatiron’s established network creates a “stronger, more connected ecosystem for clinical research,” accelerating impact and advancing the shared mission “to bring new treatments to patients faster.”
The $78 million in Series B funding is intended to fuel this network expansion, particularly targeting underserved community markets.
Source: https://www.bioxconomy.com/clinical-and-research/untitled
